The evidence is overwhelming, and the law is clear. Under 21 U.S.C. § 812(b)(1), a Schedule I placement requires demonstrating a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. The primary psychoactive alkaloids, mitragynine and 7-hydroxymitragyine act as partial and full agonists at the m-opioid receptors. 7-OH-MG exhibits higher potency at -opioid receptors than morphine, driving compulsive redosing, escalating tolerance, and physiological dependence. There is no accepted or approved medical use, and abrupt cessation in dependent individuals precipitates a classic opioid withdrawal syndrome.